Category Archives: Cancer Research

Tempus Founder Seeks to Make Data Driven Cancer Treatment

In the Tech News Spy article, “Tempus, Eric Lefkofsky, and the Rise of Data-Enabled Precision Medicine” Heidi Harris discusses the serial entrepreneur’s goals for his new company.

The article begins with several frightening statistics. 40% of American adults will be diagnosed with cancer at some point in their lives. By 2024, the National Cancer Institute expects close to 19 million citizens to be diagnosed with cancer.

Many, including Eric Lefkofsky, originally believed that the healthcare industry using the latest technology to drive more accurate treatments. However, when his wife was diagnosed with breast cancer, Mr. Lefkofsky discovered an uncomfortable truth. Despite having updates like electronic health records, the health industry did not have adequate data collection and digital technology despite the abundance of information being produced.

Data centering on the patients and the treatments may be abundant, but there was never a method to actually make use of the information. Tempus seeks to remedy that. It seeks to create a paradigm shift in cancer treatment by developing a digital library and platform. This platform will interpret the personal molecular data of the patient as well as the clinical information to provide individualized cancer treatment to each patient.

The company had several roadblocks along the way such as discovering accessible and affordable molecular, medical, and clinical data. Not to mention it also had to reorganize physicians notes to obtain the information. The company solved the issue by developing a software with machine learning, including language processing and character recognition abilities. The notes could then be transformed into data that could be applied to the treatment and care of cancer patients.

The company also uses human genome sequencing to fight the disease on the cellular and molecular level. The clinical information combined with the molecular information creates a personalized treatment plan. As the company gains more and more information, it will be able to provide a more precise medicine.

Eric Lefkofsky began the Tempus journey after discovering the issue when his wife was diagnosed. He co-founded the company in 2016. However, it is not his first journey in the entrepreneurial world. He co-founded several companies such as InnerWorkings, Echo Global Logistics, Mediaocean, and Groupon.

However, he is also a dedicated philanthropist. He began the Lefkofsky Foundation with his wife in 2006 to support educational and scientific organizations around the world. He also joined The Giving Pledge in 2013.

Oncotarget: Keeping E-Cigarette Users Informed of the Possible Dangers of Indulging

A restorative report performed by the University of Rochester Medical Center demonstrates that electronic cigarettes can harm gums and teeth similarly as seriously a conventional cigarette. The younger generation sees electronic cigarettes as a healthier choice versus traditional cigarettes. The Oncotarget was the primary source to distribute and publish these findings.

What is Oncotarget?

The Oncotarget is a therapeutic publication that gives access freely to the medical community. It was launched in 2010, and Oncotarget has been covering all parts of Oncology ever since. It incorporates new discoveries, research, studies, and it is also peer-evaluated. Oncotarget is a week by week journal, and it was the leading publication to show the findings of the harm e-cigarettes can do to the user’s oral health. The journal is peer reviewed and is published by Impact Journals.

Why are E-Cigarettes Bad for Your Oral Health?

When you smoke an e-cigarette, it discharges vapors that send signs to your mind, and your mind releases anti-inflammatories. Once these operators are released, the stress levels of the gums and rise. Overexposure to stress can be harmful to the cells and prompt gum disease, inflammation, and irritation. The medical study demonstrated that particular e-cigarette flavorings were more harmful than others, and e-cigarettes do contain nicotine as well. The e-cigarette is comprised of a battery, a tube to hold the e-juice, and a warming chamber that heats the fluid and transforms the juice into a vapor, and this is the thing that the user breathes in.

The discoveries by Oncotarget can be groundbreaking to the younger generation who smoke e-cigarettes. If the smokers are kept educated of the dangers of smoking their e-cigarettes, they can better prepare for the medical issues that could arise later in their lives. This investigation and Oncotarget are endeavoring to keep individuals up to speed with medical problems. Oncotarget is also available on Dove Press.

Clay Siegall And The Relevance Of His Support To Cancer Research

Research projects directed towards looking for solutions to the cancer menace have been around for many years. Experts like Clay Siegall have been working together to deliver solutions that are reliable and capable of offering a permanent cure. One of the research institutes that have pursued this course diligently is Seattle Genetics, which was founded in 1998 by Clay Siegall with help from several other experts. Seattle Genetics has made great steps towards delivering reliable ways of combating the effects of cancer and one of the options the company pursued is the ADC Technology, which offers a better solution to cancer treatment.

The ADC Technology is designed to work with only those cells that are affected, deliberately ignoring those that that are healthy. In the traditional method of radiating rays on the cancer cells, specialists could not avoid killing healthy cells. This process of interfering with cells that were not infected further weakened the patient and led to the development of many other problems that would later prove fatal. However, with the ADC Technology, this is no longer something to worry about since the technology allows experts to focus on the cells that are affected and allow patients to heal without experiencing other problems.

About Clay Siegall

Clay Siegall, a highly experience and skilled clinical scientist, is the CEO of Seattle Genetics, a leading company in the cancer research industry. Seattle Genetics, under the leadership of Clay Siegall, has seen a growth in its shares and is now among the best providers of solutions to the cancer menace. Clay Siegall has been choosing professionals to join the team of researchers and his company has facilitated research and the development of new drugs.

After achieving their goal of making better drug pipelines, Seattle Genetics saw its revenues rise in the past five years. Clay Siegall has also helped the company to partner with other leading players in the industry to strengthen the fight against cancer. Some of the companies he invited include Pfizer, GlaxoSmithKline and AbbVie, which have been offering support to the development of new drug pipelines and methods of treating cancer.